Company |
Product |
Description |
Indication |
Status |
Date |
Alimera Sciences Inc., of Atlanta |
Iluvien (fluocinolone acetonide intravitreal implant) |
Corticosteroid |
Diabetic macular edema |
Approved by Australian Therapeutic Goods Administration for use in patients previously treated with a course of corticosteroids who did not have clinically significant rise in intraocular pressure |
8/5/19 |
Ascletis Pharma Inc., of Hangzhou, China |
ASC-18 |
Single-pill, once-daily fixed-dose antiviral combination |
Hepatitis C virus |
Received IND approval from China's NMPA |
8/5/19 |
Daiichi Sankyo Co. Ltd., of Tokyo |
Turalio (pexidartinib) |
CSF1R inhibitor |
Tenosynovial giant cell tumor |
FDA approved for use in adults with symptomatic TGCT associated with severe morbidity or functional limitations and not responsive to improvement with surgery |
8/2/19 |
Sumitomo Dainippon Pharma Co. Ltd., of Osaka, Japan |
Lurasidone hydrochloride |
Atypical antipsychotic |
Schizophrenia and bipolar depression |
Submitted NDA for approval in Japan |
8/1/19 |
Vivus Inc., of Campbell, Calif. |
Qsymia (phentermine and topiramate extended release) |
Anti-obesity compound |
Weight loss |
Approved by South Korea Ministry of Food and Drug Safety; marketed in South Korea by partner Alvogen Korea Ltd. |
8/5/19 |
Notes The date indicated refers to the BioWorld Regulatory actions table in which the news item can be found. For more information about individual companies and/or products, see Cortellis. |
To read more on related topics, click on one of the words below.